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Abstract 
Background 
Clinical reports suggest that rather than directly driving cocaine use, stress may create a biological context 
within which other triggers for drug use become more potent. We hypothesize that stress-induced increases 
in corticosterone“set the stage” for relapse by promoting endocannabinoid-induced attenuation of inhibitory 
transmission in the prelimbic cortex (PL). 
Methods 
We have established a rat model for these stage-setting effects of stress. In this model, neither a stressor 
(electric footshock) nor stress-level corticosterone treatment alone reinstates cocaine seeking following self-
administration and extinction, but each treatment potentiates reinstatement in response to an otherwise 
subthreshold cocaine priming dose (2.5 mg/kg, intraperitoneal). The contributions of endocannabinoid signaling 
in the PL to the effects of stress-level corticosterone on PL neurotransmission and cocaine seeking were 
determined using intra-PL microinfusions. Endocannabinoid-dependent effects of corticosterone on 
inhibitory synaptic transmission in the rat PL were determined using whole-cell recordings in layer V pyramidal 
neurons. 
Results 
Corticosterone application attenuated inhibitory synaptic transmission in the PL via cannabinoid receptor type 1 
(CB1R)– and 2-arachidonoylglycerol–dependent inhibition of gamma-aminobutyric acid release without altering 
postsynaptic responses. The ability of systemic stress-level corticosterone treatment to potentiate cocaine-
primed reinstatement was recapitulated by intra-PL injection of corticosterone, the CB1R agonist WIN 55,212-2, 
or the monoacylglycerol lipase inhibitor URB602. Corticosterone effects on reinstatement were attenuated by 
intra-PL injections of either the CB1R antagonist, AM251, or the diacylglycerol lipase inhibitor, DO34. 
Conclusions 
These findings suggest that stress-induced increases in corticosterone promote cocaine seeking by mobilizing 2-
arachidonoylglycerol in the PL, resulting in CB1R-mediated attenuation of inhibitory transmission in this brain 
region. 
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Despite efforts to identify effective treatment strategies for patients with substance use disorders (SUDs), 
relapse rates remain high. This prevalence is due in part to the complex interactions among factors that promote 
drug craving and seeking. One factor, stress, is particularly problematic, as it is prevalent in SUD populations and 
unavoidable in daily life. Although there is a well-demonstrated influence of stress on drug craving in individuals 
with SUDs 1, 2, the effects of stress on drug-seeking behavior can be complex. Emerging evidence indicates that 
stress does not always directly trigger craving but instead can increase reactivity to other relapse-inducing 
stimuli 3, 4, 5, 6. This understudied influence of stress can also be observed in rats 7, 8, 9, 10. While it has been 
established that both stress (11) and high-dose priming injections of the drug (12) can trigger reinstatement, 
under conditions in which stress does not directly trigger reinstatement it can potentiate cocaine seeking in 
response to an otherwise subthreshold priming injection of cocaine following self-administration and 
extinction 8, 10. 
Footshock-induced potentiation of cocaine seeking is glucocorticoiddependent, 
and corticosterone administration at a dose that reproduces stress-induced levels is sufficient to potentiate 
reinstatement (8). A likely site of corticosterone regulation of cocaine use is the medial prefrontal cortex. The 
prelimbic region of the medial prefrontal cortex has been extensively implicated in cocaine-seeking 
behavior 13, 14, 15 and is highly regulated by stress and glucocorticoids 16, 17. Taken together, these data 
provide strong evidence that the prefrontal cortex is a key site for corticosterone actions that mediate stress 
regulation of cocaine-seeking behavior. 
Corticosterone may regulate prefrontal cortical function through interactions with the endocannabinoid system. 
In the prefrontal cortex, cannabinoid receptor type 1 (CB1R) is predominantly located on perisomatically 
targeting gamma-aminobutyric acidergic (GABAergic) interneurons (18), positioning activation of this system to 
regulate output of prefrontal pyramidal neurons. In mice, stress can increase levels of the endocannabinoid 2-
arachidonoylglycerol(2-AG) in the prefrontal cortex in a glucocorticoid-dependent manner (18). Furthermore, 
bath application of corticosterone to mouse prefrontal slices attenuates inhibitory neurotransmission in a CB1R-
dependent manner (18). Importantly, the same stressor, electric footshock, which potentiates reinstatement of 
cocaine seeking, also elevates levels of endocannabinoids in subregions of the prefrontal cortex in drug-naïve 
rats (10). Taken together, these data suggest that stress, and corticosterone, potentiate reinstatement through 
increased CB1R activation in the prelimbic cortex (PL). Importantly, we and others have demonstrated that 
systemic CB1R antagonism blocks stress-potentiated but not stress-induced 19, 20 or cocaine-
induced 10, 20reinstatement. 
In the current study, we test the hypothesis that in rats, corticosterone exerts effects in the prelimbic subregion 
of the medial prefrontal cortex to potentiate reinstatement of cocaine seeking through a CB1R-dependent 
attenuation of inhibitory neurotransmission. We demonstrate that corticosterone acts in the PL to potentiate 
cocaine seeking, and that corticosterone attenuates inhibitory neurotransmission in PL slices in a CB1R-
dependent manner. Furthermore, we show that CB1R activation in the PL is necessary for stress- and 
corticosterone-potentiated reinstatement as well as sufficient to reproduce the potentiating effects of stress or 
corticosterone administration. Finally, we determine that PL CB1R activation involves 2-AG signaling, as 
inhibition of 2-AG production blocks and attenuation of 2-AG breakdown reproduces corticosterone-potentiated 
reinstatement. 
Methods and Materials 
Subjects 
A total of 102 male Sprague Dawley rats (275 to 300 g at arrival; Envigo RMS, Inc., Indianapolis, IN), were 
individually housed in a 12-hour reverse light/dark cycle (7 am to 7 pm lights off) as described in 
the Supplement. All behavioral procedures were conducted in the dark phase. Of the rats designated 
for behavioral testing, 14 were excluded from the study because of misplaced cannulation or because they did 
not complete all behavioral testing. 
Surgery 
For intravenous self-administration and reinstatement testing, rats were anesthetized with ketamine HCl (100 
mg/kg, intraperitoneal [i.p.]; Henry Schein, Melville, NY) and xylazine (2 mg/kg, i.p.; Henry Schein) and surgically 
implanted with indwelling venous catheters. Rats that received intracranial microinfusions before reinstatement 
testing also had a bilateral guide cannulatargeting the PL. All procedures are described in detail in 
the Supplement. 
Cocaine Self-administration, Extinction, and Reinstatement 
Rats were trained to press a lever to self-administer cocaine (0.5 mg/kg/infusion) under a fixed-ratio 4 schedule 
of reinforcement during daily 2-hour sessions. Once trained, rats underwent daily self-administration for 14 days 
before extinction training, during which the cocaine solution was replaced with saline. Each rat underwent 
extinction training until extinction criterion was met (<10 lever presses/2 hours) at which point reinstatement 
testing was conducted. Procedures are described in detail in the Supplement. 
Reinstatement Conditions 
The 2-hour reinstatement sessions were preceded by footshock, corticosteroneadministration, and/or drug 
delivery, as described in the Results, and were otherwise identical to extinction conditions. A within-subject 
testing design was utilized in which each rat received all treatments in a given experiment in a counterbalanced 
order. Nine rats did not complete all tests and were excluded from the study. Reinstatement was defined as 
significantly increased responding on the lever previously reinforced by cocaine relative to the preceding 
extinction session and compared with control conditions. Responding on a second lever that was inactive 
through self-administration training was also recorded during the sessions. There were no significant changes in 
inactive lever responding between extinction and reinstatement testing days (Supplemental Figure S3). 
Potentiated cocaine seeking was defined as significant reinstatement in response to low-dose cocaine (2.5 
mg/kg, i.p.) following shock or drug pretreatment under conditions where neither low-dose cocaine nor the drug 
pretreatment alone produced reinstatement. 
Intracranial Drug Administration 
Intra-PL infusions were given at various time points before reinstatement testing as described in the Results. All 
infusions were a volume of 0.3 μL at a rate of 0.3 μL/min. Placement of the guide cannula was verified as 
described in the Supplement. Albeit in only 5 rats, injections outside of the PL did not have effects on cocaine-
seeking behavior. 
Slice Electrophysiology 
Whole-cell voltage clamp recordings were made from pyramidal neurons in layer V of the PL of drug-naïve rats 
as described in detail in the Supplement. For recording of evoked inhibitory postsynaptic currents (IPSCs), layer 
V pyramidal neurons were voltage-clamped at −60 mV, and IPSCs were evoked at 0.05 Hz by 
a tungsten stimulation electrode placed near the apical dendrites. Spontaneous miniature IPSCs (mIPSCs) were 
recorded from the pyramidal neurons at a holding potential of −70 mV. Action potential generation was blocked 
with tetrodotoxin (0.5 μM). Glutamate receptor antagonists 6-cyano-7-nitroquinoxaline-2,3-dione (10 μM) and 
D-2-amino-5-phosphonovaleric acid (20 μM) were present in the artificial cerebrospinal fluid throughout the 
experiments. Series resistance (15 to 30 MΩ) was monitored throughout the recordings, and data were 
discarded if the resistance changed by more than 20%. All recordings were performed at 32 ± 1°C. 
Mass Spectrometry 
To determine if the diacylglycerol lipase (DAGL) inhibitor DO34 attenuates corticosterone-induced 2-AG levels, 
rats received intra-PL infusions of DO34 (1 μg/0.3 μL) or vehicle (70% dimethyl sulfoxide) 30 minutes before a 
corticosterone (2 mg/kg, i.p.) or vehicle (10% ethanol) injection. Rats were rapidly decapitated 45 minutes 
following the injection and brains were removed within 90 seconds, frozen in liquid nitrogen, and stored 
at −80°C. The PL was dissected and endocannabinoids extracted as previously described (10). N-
arachidonoylethanolamine and 2-AG were isolated and quantified as described in 
the Supplement using isotope dilution and liquid chromatography/mass spectrometry. 
Statistical Analysis 
Statistical analyses were conducted using one- or two-way repeated-measures (RM) analysis of variance 
(ANOVA), followed by Bonferroni post hoc tests when appropriate for behavioral and mass 
spectrometry experiments and Student’s ttest for electrophysiology experiments (see the Supplement for more 
detail). 
Results 
Corticosterone Acts in the PL to Potentiate Reinstatement 
After 14 days of stable cocaine self-administration, responding was extinguished and rats were tested for 
reinstatement of cocaine seeking. All self-administration and extinction data are displayed in Supplemental 
Table S1. As previously reported under these conditions 8, 10, electric footshock stress (3 × 0.5 mA, 200-ms 
duration, mean intershock interval 40 seconds, range 10 to 70 seconds over a 15-minute period) alone did not 
induce reinstatement, but rather potentiated cocaine seeking in response to an otherwise subthreshold priming 
dose of cocaine (2.5 mg/kg, i.p.; Figure 1A; two-way RM ANOVA, reinstatement condition × day interaction 
[F3,15 = 17.11, p < .001], post hoc comparison, shock/cocaine combination vs. extinction, p < .05). The ability of 
footshock to potentiate reinstatement was reproduced by systemic administration of corticosterone (2 mg/kg, 
i.p.) at a dose that established footshock-induced levels of plasma corticosterone (Supplemental Figure S1). As 
with footshock, corticosterone alone was insufficient to induce reinstatement. However, when corticosterone 
was combined with an otherwise subthreshold priming injection of cocaine, significant reinstatement was 
observed (Figure 1B; two-way RM ANOVA, reinstatement condition × day [F3,12 = 10.30, p < .001], post hoc 
comparison, corticosterone/cocaine combination vs. extinction, p < .05). To localize corticosterone action in the 
brain, soluble 2-hydroxypropyl-β-cyclodextrin–conjugated corticosterone (50 ng/0.3 μL), was microinfused 
directly into the PL 10 minutes before low-dose cocaine. As was the case with systemic administration, intra-PL 
administration of corticosterone alone did not increase cocaine seeking, but rather induced significant 
reinstatement when given before administration of the subthreshold priming dose of cocaine (Figure 1C; two-
way RM ANOVA, reinstatement condition × day interaction [F2,12 = 4.89, p < .05], post hoc comparison, 
corticosterone/cocaine combination vs. extinction, p < .05). These findings identify the PL as an important site 
for corticosterone effects on cocaine seeking. 
 
Figure 1. Corticosterone (CORT) acts in the prelimbic cortex to potentiate reinstatement of cocaine (COC) 
seeking. (A) Electric footshock stress (SHOCK) (n = 6) potentiates reinstatement when given in combination with a low 
dose of cocaine (COC) (2.5 mg/kg, intraperitoneal [i.p.]). (B) Systemic corticosterone (2 mg/kg, i.p.; n = 5) reproduces the 
effect of footshock and potentiates reinstatement when given 40 minutes before an injection of low-dose cocaine (2.5 
mg/kg, i.p.). (C) 2-Hydroxypropyl-β-cyclodextrin (HBC)–conjugated corticosterone (50 ng/0.3 μL; n = 7) administered directly 
into the prelimbic cortex (PL) 10 minutes before a low-dose cocaine injection (2.5 mg/kg, i.p.) induces significant 
reinstatement whereas either administered alone does not (p < .05; **p < .01, *p < .05, compared with 
extinction). (D) Injection needle tips of all rats included in the intra-PL corticosterone experiment. Data are presented as 
mean ± SEM. 
 
Corticosterone Attenuates PL Inhibitory Neurotransmission in a CB1R-Dependent 
Manner 
To investigate corticosterone effects on PL neurotransmission in rats, whole-cell recordings were made in 
visually identified layer V pyramidal neurons in rat PL. We initially examined the effects of corticosterone on 
evoked IPSCs. Following stable baseline recordings, bath application of corticosterone (1 μM) for 30 minutes 
gradually decreased the amplitude of evoked IPSCs with the depression having a rapid onset (∼5 minutes) and 
peaking in 30 minutes (Figure 2A). This depression was accompanied by an increase in the paired-pulse ratio, 
suggesting a presynaptic mechanism (Figure 2B). The depression of evoked IPSC amplitude by corticosterone 
was prevented by the continuous presence of CB1R antagonist AM251 (2 μM; Figure 2A). Moreover, in the 
presence of AM251, paired-pulse ratio was not altered by corticosterone (Figure 2B). Thus, these results suggest 
that corticosterone depresses IPSCs in rat PL through a presynaptic CB1R-dependent mechanism. To further test 
this, we examined the effects of corticosterone on mIPSCs in layer V pyramidal neurons in rat PL slices. A change 
in mIPSC frequency indicates a presynaptic mechanism, whereas a change in mIPSC amplitude signifies a likely 
change in postsynaptic responsiveness (21). PL slices were perfused with either vehicle or corticosterone (1 μM) 
for 20 to 60 minutes, and mIPSCs were recorded from layer V pyramidal neurons. Corticosterone perfusion 
significantly decreased the frequency of mIPSCs (Figure 2D) as shown by both a decrease in the mean frequency 
of mIPSCs (p < .01) and a rightward shift in the cumulative probability plot for interevent intervals. By contrast, 
corticosterone did not alter the mean amplitude of mIPSCs (Figure 2E; p > .05) or the cumulative amplitude 
distribution (p > .05). To investigate if corticosterone depressed mIPSCs through a CB1R-dependent mechanism, 
we repeated the above experiments in the presence of the CB1R antagonist AM251. PL slices were perfused with 
either AM251 (2 μM) alone or AM251 with corticosterone (1 μM) for 20 to 60 minutes. In the presence of 
AM251, corticosterone did not significantly alter mIPSCs (Figure 2D; p > 05) as there were no significant changes 
in the mean frequency of mIPSCs (p > .05) or the cumulative interevent interval probability plot (p >.05). In the 
presence of AM251, corticosterone did not significantly alter the mean amplitude of mIPSCs (Figure 2E; p > .05) 
or cumulative amplitude distribution (p > .05). These results suggest that corticosterone-induced depression of 
mIPSCs in the PL is dependent on presynaptic CB1R-mediated suppression of GABAergic transmission. 
 
Figure 2. Corticosterone (Cort) depressed evoked and miniature inhibitory postsynaptic currents (mIPSCs) through 
a cannabinoid receptor type 1 (CB1R)–dependent mechanism in rat prelimbic cortex (PL) slices. (A) Bath application of 
corticosterone (1 μM) caused rapid depression of evoked IPSCs (n = 10 neurons; n = 2-3 rats) in layer V pyramidal neurons in 
the prelimbic cortex (PL), which were blocked by the CB1R antagonist AM251 (2 μM, n = 11 neurons; n = 2–3 rats). (B) Bath 
application of corticosterone increased the paired-pulse ratio, which was blocked by AM251 (n = 11 neurons; n = 2–3 rats, p 
< .05). (C) Representative traces of mIPSCs recorded in layer V pyramidal neurons in PL slices that were treated with vehicle 
(control), corticosterone (1 μM), AM251 (2 μM), or AM251 plus corticosterone (1 μM). (D) Corticosterone treatment 
decreased the mean frequency of mIPSCs (n = 9–11 neurons; n = 2–3 rats, p < .01) and caused a right shift of the interevent 
intervals of the cumulative probability plot. However, in the presence of AM251, corticosterone did not alter the mean 
frequency of mIPSCs (n = 10–11 neurons; n = 2–3 rats, p > .05) or interevent intervals of the cumulative probability 
plot. (E) Corticosterone did not alter the mean amplitude of mIPSCs (p > .05) and cumulative amplitude distribution. In 
addition, in the presence of AM251, corticosterone had no significant effect on the mean amplitude of mIPSCs (p > .05) or 
on the cumulative amplitude distribution of mIPSCs. 
 
CB1R Activation in the PL Is Necessary and Sufficient for Stress- and Corticosterone-
Potentiated Reinstatement 
We have previously shown that stress-potentiated reinstatement is prevented by systemic administration of the 
CB1R antagonist, AM251 (10). These data, in combination with the observed CB1R-dependent corticosterone 
attenuation of PL inhibitory neurotransmission, led us to hypothesize that stress-potentiated reinstatement is 
mediated by corticosterone-regulated endocannabinoidsignaling and PL CB1R activation. Consistent with this 
possibility, intra-PL administration of AM251 (300 ng/0.3 μL) 15 minutes before footshock blocked stress-
potentiated reinstatement (Figure 3A; two-way RM ANOVA, reinstatement condition × day interaction [F3,15 = 
15.71, p < .001]; post hoc comparison, vehicle/shock/cocaine combination vs. extinction, p < .05; 
AM251/shock/cocaine combination vs. extinction, p > .05). Moreover, intra-PL administration of AM251 (300 
ng/0.3 μL) 15 minutes before systemic corticosterone administration (2 mg/kg, i.p.) also blocked corticosterone-
potentiated reinstatement (Figure 3B; two-way RM ANOVA, reinstatement condition × day interaction [F3,15 = 
6.94, p < .01], post hoc comparison, vehicle/corticosterone/cocaine combination vs. extinction, p < .05; 
AM251/corticosterone/cocaine combination vs. extinction, p > .05). These data provide compelling evidence 
that stress, likely through corticosterone, promotes cocaine seeking via increased endocannabinoid signaling in 
the PL. To determine if CB1R activation in the PL is sufficient to potentiate cocaine-primed reinstatement, we 
tested rats for the effects of the intra-PL delivery of the CB1R agonist WIN 55,212-2 on reinstatement. Neither 
intra-PL WIN 55,212-2 (50 ng/0.3 μL; 15-minute pretreatment) nor 2.5 mg/kg (i.p.) cocaine alone increased 
cocaine seeking. However, when intra-PL WIN 55,212-2 preceded the cocaine injection, significant 
reinstatement was observed (Figure 4A; two-way RM ANOVA, reinstatement condition × day interaction [F2,10 = 
7.09, p < .05], post hoc comparison WIN/cocaine combination vs. extinction, p < .05). 
 
Figure 3. Stress- and corticosterone-potentiated reinstatement is blocked by cannabinoid receptor type 1 (CB1R) 
antagonism in the prelimbic cortex (PL). (A)Electric footshock stress (SHOCK)–potentiated reinstatement to low-
dosecocaine (COC) (2.5 mg/kg, intraperitoneal [i.p.]) is blocked by pretreatment with an intra-PL infusion of the CB1R 
antagonist AM251 (300 ng/0.3 μL) 15 minutes before the reinstatement test (n = 6, *p < .05, compared with 
extinction). (B)Corticosterone (CORT) (2 mg/kg, i.p.)–potentiated reinstatement to low-dose cocaine is blocked by 
pretreatment with an intra-PL infusion of AM251 15 minutes before the reinstatement test (n = 6, *p < .05, compared with 
extinction). (C) Injection needle tips of all rats included in the intra-PL AM251 experiment. Data are presented as mean 
± SEM. 
 
 
Figure 4. Cannabinoid receptor type 1 (CB1R) activation in the prelimbic cortex(PL) is sufficient to potentiate 
reinstatement. (A) Intra-PL administration of the CB1R agonist WIN 55,212-2 (WIN) (50 ng/0.3 μL) 15 minutes before a low-
dosecocaine injection (COC) (2.5 mg/kg, intraperitoneal [i.p.]) induces significant reinstatement of cocaine-seeking behavior 
while either administered alone does not (n = 6, *p < .05, compared with extinction). (B) Intra-PL administration of a 
monoacylglycerol lipase inhibitor URB602 (URB) (300 pmol/0.3 μL), which elevates 2-arachidonoylglycerol levels and acts 
an indirect agonist of CB1R, 60 minutes before a low-dose cocaine injection (2.5 mg/kg, i.p.) induces significant 
reinstatement while administration of either alone does not (n = 6, *p < .05, compared with extinction). (C) Injection needle 
tips of all rats included in the intra-PL experiment. Data are presented as mean ± SEM. 
 
There is evidence that stress can mobilize the endocannabinoid 2-AG in the PL (16), suggesting that CB1R-
dependent effects of corticosterone may be mediated through 2-AG signaling. To determine if elevated 2-AG 
levels are sufficient to potentiate reinstatement, we tested rats for the effect of intra-PL administration of 
URB602, an inhibitor of the enzyme monoacylglycerol lipase, which is responsible for the breakdown of 2-AG. As 
was the case with corticosterone and WIN 55,212-2, neither intra-PL URB602 (300 pmol/0.3 μL; 60-minute 
pretreatment) nor 2.5 mg/kg (i.p.) cocaine alone increased cocaine seeking, but significant reinstatement was 
observed when URB602 preceded the cocaine injection (Figure 4B; two-way RM ANOVA, reinstatement 
condition × day interaction [F2,10 = 5.89, p < .05], post hoc comparison URB602/cocaine combination vs. 
extinction, p < .05). Collectively, these data demonstrate that endocannabinoid signaling in the PL is necessary 
and sufficient for stress- and corticosterone-potentiated reinstatement, and suggest that corticosterone may 
potentiate reinstatement through increased 2-AG signaling. 
Corticosterone Potentiates Reinstatement Through Increased 2-AG Signaling in the PL 
To further test if PL 2-AG signaling mediates corticosterone effects on reinstatement, DO34 (provided by the 
Cravatt lab, Scripps Research Institute, La Jolla, CA), a novel inhibitor of DAGL, the synthetic enzyme for 2-AG, 
was used. Bath application of DO34 (1 μM) to PL cortical slices blocked depolarization-induced suppression of 
inhibition (n = 7 to 8, p < .01), which is CB1R dependent (18), suggesting that 2-AG signaling plays a critical role in 
endocannabinoid effects on PL neurotransmission (Figure 5A). Furthermore, intra-PL administration of DO34 (1 
μg/0.3 μL; 30-minute pretreatment) before a systemic injection of corticosterone (2 mg/kg, i.p.) significantly 
reduced PL 2-AG content in a corticosterone-dependent manner (Figure 5B; two-way ANOVA with DO34 and 
corticosterone treatments as between factors, main effect of DO34 [F1,26 = 6.97, p < .01], main effect of 
corticosterone [F1,26 = 1.98, p > .05], DO34 × corticosterone [F1,26 = 2.09, p > .05]), while having no effect on 
levels of anandamide (Supplemental Figure S2; p > .05). Confirming a role for PL 2-AG in the corticosterone-
dependent stress-induced potentiation of cocaine seeking, intra-PL administration of DO34 (0.1, 1 μg/0.3 μL; 30-
minute pretreatment) before systemic corticosterone dose-dependently inhibited the ability of stress-level 
corticosterone to potentiate cocaine seeking when combined with low-dose cocaine (Figure 5C; two-way RM 
ANOVA, reinstatement condition × day interaction [F4,16 = 3.84, p < .05], post hoc comparisons, 
vehicle/corticosterone/cocaine combination vs. extinction, p < .05; DO34 0.1/corticosterone/cocaine or DO34 
1.0/corticosterone/cocaine vs. extinction, p >.05). Taken together these data suggest that, during stress, 
corticosterone-induced PL 2-AG signaling acting via CB1Rs attenuates inhibitory neurotransmission to increase 
the excitability of cortical outputs mediating cocaine seeking, thereby promoting relapse vulnerability to 
ordinarily subthreshold triggers. 
 
Figure 5. Corticosterone (CORT)-potentiated reinstatement is dependent on 2-arachidonoylglycerol (2-AG) signaling in 
the prelimbic cortex (PL). (A) Bath application of the diacylglycerol lipase inhibitor DO34 (1 μM) to PL slices 
blocks depolarization-induced suppression of inhibition (n = 7–8, p < .01). (B) Direct administration of the diacylglycerol 
lipase inhibitor DO34 (1 μg/0.3 μL) into the PL 30 minutes before a systemic injection of corticosterone (2 mg/kg, 
intraperitoneal [i.p.]) attenuates PL 2-AG in the presence of corticosterone (n =7–8; *p < .05, main effect of 
DO34). (C) Corticosterone-potentiated reinstatement is dose-dependently blocked by intra-PL administration of DO34 (0.1 
μg/0.3 μL, 1.0 μg/0.3 μL) 30 minutes before the corticosterone injection (n = 5; *p < .05, compared with 
extinction). (D) Injection needle tips of all rats included in the intra-PL experiment. Data are presented as mean ± SEM. COC, 
cocaine injection; IPSC, inhibitory postsynaptic currents; Sac, sacrifice animal. 
 
Discussion 
Stress is a powerful determinant of drug seeking in individuals with SUDs. This is problematic for relapse 
prevention, as stress is prevalent and unavoidable in the daily lives of drug addicts. Although the general idea 
that stress contributes to drug seeking is well established 22, 23, 24, the nature of this contribution appears to 
be more complex than previously thought. While it is true that in some cases, stress can serve as a direct 
trigger for drug craving 2, 11, supported by findings in rodent models (11), recent evidence points to a more 
opportunistic role of stress that involves interactions with other factors that promote relapse [e.g., cues, drug 
re-exposure; 4, 5, 25]. Consistent with reports from individuals with SUDs, these findings imply that stress may 
function by augmenting the ability of other stimuli to elicit drug seeking, thereby “setting the stage” for relapse. 
We have recently established a preclinical model for these stage-setting effects of stress wherein stress can 
potentiate, but not directly trigger, reinstatement of cocaine seeking in response to an otherwise subthreshold 
priming injection of cocaine 8, 10. Similarly, it has been reported that stress can potentiate the reinstatement of 
drug seeking upon the presentation of drug-associated cues 7, 9, 26. Importantly, evidence suggests that the 
neurobiological processes that mediate stress-potentiated reinstatement are distinct from those that mediate 
stress-triggered cocaine seeking. Specifically, shock-potentiated cocaine seeking, observed in rats with a history 
of shorter daily access to cocaine, requires acute elevation of corticosterone (8) and CB1R activation (10), while 
shock-triggered cocaine seeking, observed in rats with a history of longer daily access to cocaine, does 
not 10, 26. 
Here we identify the prelimbic subregion of the medial prefrontal cortex as a critical site of action for the 
corticosterone-dependent stage-setting effects of stress on cocaine seeking. We demonstrate that the ability of 
stress and stress-level corticosterone to potentiate cocaine-induced reinstatement is reproduced by intra-PL 
corticosterone delivery. The PL has been previously implicated in drug seeking in response to multiple 
reinstating stimuli 13, 14, 15 and is critical for the control of goal-directed behavior (27). Moreover, the medial 
prefrontal cortex is highly responsive to stress, as it contains a high density of glucocorticoid 
receptors 28, 29 and is heavily regulated by corticosterone, which acts in the region to exert negative 
feedback on the hypothalamic-pituitary-adrenal axis 18, 30 and modify neuronal morphology 31, 32, gene 
transcription33, 34, synaptic physiology 18, 35, 36, 37, 38, and behavior 39, 40, 41, 42. 
In the PL, corticosterone likely regulates cocaine seeking through a CB1R-dependent attenuation of 
GABAergic neurotransmission. Here we report that both stress- and corticosterone-potentiated reinstatement 
are prevented by intra-PL administration of the CB1R antagonist AM251, while intra-PL administration of the 
CB1R agonist WIN 55,212-2 is sufficient to potentiate cocaine-induced reinstatement. The PL CB1Rs are located 
predominately on GABAergic interneurons (18) and activation of CB1Rs in the prefrontal cortex attenuates 
inhibitory neurotransmission (43). In mice, ex vivo bath application of corticosterone to medial prefrontal cortex 
slices produces a CB1R-dependent reduction in inhibitory neurotransmission (18). Furthermore, we demonstrate 
that bath application of corticosterone to rat PL slices attenuates both spontaneous and evoked inhibitory 
neurotransmission via a CB1R-dependent presynaptic mechanism in rats. 
The effects of stress and corticosterone on reinstatement likely involve mobilization of 2-AG in the PL. Prior 
studies have suggested that stress and glucocorticoids mobilize 2-AG 44, 45, particularly in the prefrontal 
cortex (18). Here we report that intra-PL delivery of a monoacylglycerol lipase inhibitor, URB602, which elevates 
2-AG brain content 46, 47, is sufficient to potentiate reinstatement in response to low-dose cocaine, similar to 
what is observed with stress, corticosterone, and intra-PL CB1R agonist administration. However, a role 
for anandamide signaling was not examined in the current study and cannot be ruled out. To determine if 
corticosterone potentiates reinstatement through 2-AG mobilization, we utilized a novel DAGL inhibitor, DO34, 
which reduces 2-AG brain content (48). Bath application of DO34 blocks depolarization-induced suppression of 
inhibition in the PL, which is known to be CB1R dependent (18), suggesting that mobilization of 2-AG is critical for 
endocannabinoid-regulated synaptic plasticity, while intra-PL DO34 both prevents corticosterone-potentiated 
reinstatement and reduces PL 2-AG content in corticosterone-treated rats without altering anandamide levels. 
Interestingly, while intra-PL administration of the DAGL inhibitor DO34 reduced 2-AG content in corticosterone-
treated rats, a corticosterone-induced elevation of PL 2-AG was not observed, in contrast to earlier studies 
demonstrating glucocorticoid-dependent stress-induced mobilization of 2-AG (16). However, these findings are 
consistent with reports that systemic administration of corticosterone alone does not elevate anandamide or 2-
AG in the prefrontal cortex as observed with bulk tissue dissection (49). Given that a majority of brain tissue 2-
AG content is not involved in signaling (50), tissue concentration of 2-AG may not be sensitive to an increase in 
2-AG mobilization at the synapse. The mechanism through which corticosterone regulates 
PL endocannabinoid signaling is unclear and will require further investigation. 
Our data suggest that corticosterone potentiates reinstatement through an endocannabinoid-mediated, likely 2-
AG, attenuation of inhibitory neurotransmission, which should increase the excitability of outputs mediating 
drug seeking. This is supported by findings that acute stress recruits endocannabinoid signaling, specifically 2-
AG, to attenuate inhibitory neurotransmission in the basolateral amygdala (44). While the current study did not 
directly examine specific PL projection fields, the projection pathway from the PL to the nucleus accumbens 
core is one likely to be affected as it has been established as a key pathway for cocaine 
seeking 13, 14, 15, 51, 52, 53. Specifically, we hypothesize that corticosterone mobilizes 2-AG, thereby activating 
CB1Rs that regulate GABA release from cortical interneurons, to attenuate inhibitory regulation of cortico-
accumbens pyramidal projection neurons. This disinhibition would render the cortico-accumbens pathway more 
responsive to convergent PL excitatory inputs, including those activated by stimuli that trigger cocaine seeking. 
This hypothesis is consistent with a previous report that attenuated GABAergic neurotransmission in the medial 
prefrontal cortex facilitates cue-induced reinstatement to nicotine seeking (54). However, this requires further 
study, as it is unknown whether corticosterone-potentiated reinstatement results in increased activation of the 
cortico-accumbens pathway, and there are several possible PL projection pathways that can regulate 
potentiated cocaine seeking. Furthermore, while CB1Rs are predominantly on GABAergic terminals in the PL, it is 
not currently known whether corticosterone can potentially regulate neurotransmission in a CB1R-dependent 
manner through non-GABAergic mechanisms. 
While our findings demonstrate that the PL is an important site for corticosterone effects, it is not the only site 
at which corticosterone can regulate cocaine seeking. This may contribute to the differential magnitude of 
reinstatement observed with intraperitoneal versus intra-PL administration of corticosterone. We previously 
reported that corticosterone delivery into the nucleus accumbens can also potentiate cocaine-induced 
reinstatement in rats. However, the effects of corticosterone in the nucleus accumbens involve its inhibition of 
organic cation transporter 3, a secondary uptake mechanism for monoamines, and the resulting decrease in 
dopamine clearance (8). However, there is likely interplay between the two brain regions, and others, during 
reinstatement. Furthermore, it is possible that organic cation transporter 3 and endocannabinoid mechanisms 
may work in tandem within the PL itself. Ultimately, the ability of corticosterone to regulate behavior at multiple 
sites suggests that during periods of stress, glucocorticoids may impose a brain state that produces system-wide 
changes in synaptic transmission to promote adaptive behavioral response patterns. The ubiquitous nature of 
endocannabinoid signaling suggests that glucocorticoid mobilization of 2-AG may serve as a key mechanism 
through which stress shifts neuronal excitabilityand therefore influence behavior at the network level. 
The complexity of the contribution of stress to drug seeking has limited our ability to develop effective strategies 
for relapse prevention aimed at targeting stress-responsive mechanisms. Here we report that stress, under 
conditions in which it does not directly trigger responding, can potentiate cocaine-induced reinstatement in a 
rodent model, thereby setting the stage for cocaine seeking. This approach is consistent with many clinical 
reports and therefore may offer greater validity for studying the contribution of stress to relapse. Importantly, 
the observation that the neurobiological mechanisms underlying these “stage-setting” effects of stress are 
distinct from those through which stress triggers cocaine seeking, suggests that this model has the potential to 
reveal new targets for relapse prevention. 
Finally, while our findings have direct implications for understanding SUDs, the ability of stress to modify 
synaptic transmission and neuronal excitability in the PL via glucocorticoid regulation of endocannabinoid 
signaling has important implications for a range of stress-related pathological conditions that have been 
associated with prefrontal cortical dysregulation. 
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Stress Promotes Drug Seeking Through Glucocorticoid-Dependent Endocannabinoid Mobilization in Prelimbic 
Cortex 
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Supplemental Methods and Materials 
Subjects: Male Sprague-Dawley rats (275-300g at arrival) obtained from Envigo (Indianapolis, IN) were 
individually housed in a humidity- and temperature-controlled, AAALAC-accredited facility with ad libitum access 
to food and water. Rats were housed under a 12-h/12-h reverse light/dark cycle (0700-1900 lights off). For 
electrophysiology experiments, male Sprague-Dawley rats (200-250g at arrival) were obtained from Charles 
River laboratories (Wilmington, MA). All behavioral procedures were completed in the dark phase of the light 
cycle. All experimental procedures were carried out in compliance with National Institutes of Health Guidelines 
and were approved by Institutional Animal Care and Use Committees (Marquette University and Medical College 
of Wisconsin). 
Surgery: For intravenous cocaine self-administration, rats were anesthetized with ketamine HCl (100 mg/kg, i.p.; 
Henry Schein, Melville, NY) and xylazine (2 mg/kg, i.p.; Henry Schein, Melville, NY) and had an indwelling venous 
catheter implanted surgically. The polyurethane (0.6 mm i.d. x 1.1 mm o.d.; Access Technologies, Skokie, IL) 
catheters were connected to a back-mounted cannula (Plastics One, Roanoke, VA) attached to polypropylene 
mesh (500 microns; Small Parts, Logansport, IN). Catheters were implanted into the superior vena cava with the 
back-mount placement situated approximately 1 inch behind the scapula. For rats that received intra-prelimbic 
cortical (PL) infusions prior to reinstatement testing, guide cannula were surgically implanted immediately 
following catheter surgery. For guide cannula implantation, the skull was positioned  n a stereotaxic frame 
(Stoelting Inc; Wood Dale, IL) and two 11-mm stainless steel guide cannula (26 gauge; Plastics One, Roanoke, 
VA) were positioned 0.5 mm above the PL [coordinates (in mm): anteroposterior (A/P): +2.8 from Bregma; 
mediolateral (M/L): +1.0 from midline; dorsoventral (D/V): -3.5 from the skull surface; incisor bar: -3.3 from 
interaural line (Paxinos and Watson, 2005)]. Guide cannula were fixed in place with acrylic dental cement and 
four small anchoring screws. Internal dummy cannula were inserted into each cannula to maintain patency. Rats 
were given Bio-Serv Rimadyl tablets (5 g; Fisher Scientific; Hampton, NH) in their cage for 3 days and antibiotic 
treatment (100 mg/kg, iv; Cefazolin; Henry Schein, Melville, NY) for at least 5 days following surgery. All rats 
recovered for a minimum of one week before the initiation of self-administration. 
Cocaine self-administration, extinction, and reinstatement: Self-administration procedures were conducted in 
computer-interfaced operant conditioning chambers equipped with retractable levers and stimulus lights above 
each lever in sound-attenuating cubicles (MED-Associates; Fairfax, VT). Following recovery from surgery, rats 
were food deprived to 90% of their body weight and were then trained to receive sucrose pellets by pressing a 
lever under a fixed-ratio (FR) 1 schedule. Once rats successfully acquired lever pressing for food, rats were then 
switched over to self- administer cocaine (0.5 mg/kg/infusion) by pressing a lever under a FR1 schedule during 
daily 2- h sessions. Pressing the lever resulted in an infusion (200 μL over 5-sec) followed by a 10-sec time-out 
period, during which lever presses were recorded but not reinforced and the stimulus light above the lever was 
extinguished and the house light turned on. Responding on a second, inactive lever was also recorded but not 
reinforced. Following stable responding, the FR value was increased gradually to FR4. Once stable responding on 
FR4 was maintained (<10% change over 3 days), rats were provided access to cocaine for self-administration 
during daily 2-h sessions for 14 days. Rats then underwent extinction training, wherein the cocaine syringe was 
replaced with saline, until the extinction criterion was met (<10 lever presses/2 h). Once rats met this criterion, a 
reinstatement test was conducted the following day. 
Reinstatement conditions: The 2-h reinstatement tests were preceded by footshock, corticosterone, and cocaine 
and/or drug delivery but were otherwise identical to extinction conditions. A complete within-subjects design 
was used wherein all rats underwent multiple reinstatement tests within each experiment in a counterbalanced 
fashion for a maximum of 6 reinstatement tests. Rats that did not complete all reinstatement tests were 
excluded from analysis. Rats were given additional extinction/washout sessions between reinstatement tests to 
reestablish extinction criterion (<10 lever presses/2 h) before receiving additional tests. For stress-potentiated 
reinstatement of cocaine seeking, the electric footshock stress (3 x 0.5 mA, 200-msec duration, mean intershock 
interval 40-sec, range 10-70-sec over a 15-min period) was administered through stainless steel grid floors. 
Immediately following cessation of the electric footshock stress, a subthreshold dose of cocaine (2.5 mg/kg, i.p.) 
or saline was given followed by the 2-h reinstatement session. For corticosterone- potentiated reinstatement of 
cocaine seeking, a systemic injection of corticosterone (2 mg/kg, i.p) or vehicle (10% EtOH) was administered 40-
min prior to an injection of low-dose cocaine (2.5 mg/kg, i.p) or saline, followed by the 2-h reinstatement 
session. 
Intra-cranial drug administration: HBC-conjugated corticosterone (50 ng/0.3 µL; Sigma-Aldrich, St. Louis, MO), 
the CB1R antagonist AM251 (300 ng/0.3 µL; Sigma-Aldrich, St. Louis, MO), the CB1R agonist WIN 55,212-2 (50 
ng/0.3 µL; Sigma-Aldrich, St. Louis, MO), the MAGL inhibitor URB602 (300 pmol/0.3 µL; Tocris, Bristol UK), or the 
DAGL inhibitor DO34 (0.1, 1.0 µg/0.3 µL; Cravatt Lab, Scripps Research Institute) were micro-infused directly into 
the PL at various times prior to reinstatement testing as described in the Results section. Infusion needles were 
comprised of 11.5 mm 30-gauge stainless steel injectors (Plastics One, Roanoke, VA) attached to polyethylene-
20 tubing and Hamilton syringes. The vehicle or drug was backfilled into the infusion needle and all drugs were 
infused at a volume of 0.3 µL and at a rate of 0.3 µL/min using a syringe pump. The needles remained in place 
for an additional 1-min to allow for diffusion. 
Trunk blood collection and plasma corticosterone analysis: To confirm that the systemic dose of corticosterone 
used in the study recapitulates stress-evoked increases in blood levels of corticosterone, plasma corticosterone 
levels were quantified by radioimmunoassay (RIA) following either electric footshock stress or systemic 
corticosterone administration. Some rats received the same 15-min intermittent electric footshock stress 
parameters used for behavioral testing, and were sacrificed immediately after cessation of the footshock. Other 
rats were assigned to a No Shock control wherein rats were placed in the self-administration chamber for 15 min 
and were sacrificed immediately afterward. Another group of rats were given a systemic injection of 
corticosterone (2 mg/kg, i.p.) or vehicle (10% EtOH) and were sacrificed 40-min after the injection. All animals 
were sacrificed by rapid decapitation, and trunk blood collected for analysis. Trunk blood was collected into 
centrifuge tubes containing heparin and the blood was spun in a centrifuge at 1000 x g for 10-min to separate 
the plasma. The plasma was transferred into a new tube and stored at −80°C for long-term storage. 
Corticosterone levels in plasma were determined by using a 3H-Corticosterone RIA kit (MP Biomedicals, Santa 
Ana, CA) according to the manufacturer protocol. 
Slice electrophysiology: Drug-naïve rats were anaesthetized by isoflurane inhalation and decapitated. Cortical 
slices were cut using a vibrating slicer (Leica, Wetzler, Germany). The slices were transferred into artificial 
cerebrospinal fluid (ACSF) containing (in mM): 119 NaCl, 2.5 KCl, 2.5 CaCl2, 1 MgCl2, 1.25 NaH2PO4, 26 NaHCO3, 
and 10 glucose, and allowed to recover at least one hour at room temperature. All solutions were saturated with 
95% O2 and 5% CO2. Whole-cell voltage clamp recordings were made using a patch clamp amplifier (Multiclamp 
700B; Molecular Devices, Sunnyvale, CA) under infrared-differential contrast interference microscopy. Data 
acquisition and analysis were performed using a digitizer (DigiData 1440A; Molecular Devices, Sunnyvale, CA) 
and analysis software pClamp 10 (Molecular Devices, Sunnyvale, CA). Pyramidal neurons in layer V of the PL 
were identified visually based upon pyramidal-shaped soma with a prominent apical dendrite. Additionally, the 
pyramidal neurons exhibit spike frequency adaptation in response to depolarizing current injections  (1). For 
recording of evoked  IPSCs, layer V pyramidal neurons were voltage-clamped at −60 mV, and IPSCs were evoked 
at 0.05 Hz by a tungsten stimulation electrode placed near the apical dendrites. The pipettes were filled with an 
internal solution containing (in mM): 80 K-gluconate, 60 KCl, 10 HEPES, 0.2 EGTA, 2 MgCl2, 2 Mg-ATP, 0.3 
Na2GTP, and 10 Na2-phosphocreatine (pH 7.2 with KOH). Spontaneous miniature IPSCs (mIPSCs) were recorded 
from pyramidal neurons at a holding potential of −70 mV. Action potential generation was blocked with 
tetrodotoxin (TTX; 0.5 μM). Glutamate receptor antagonists 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX, 10 
µM) and D-2-amino-5-phosphonovaleric acid (D-AP-5, 20 µM) were present in the ACSF throughout the 
experiments. Series resistance (15-30 MΩ) was monitored throughout the recordings, and data were discarded 
if the resistance changed by more than 20%. All recordings were performed at 32 ± 1°C by using an automatic 
temperature controller. 
Mass spectrometry: To assess effects of the DAGL inhibitor DO34 on corticosterone-induced 2- 
arachidonoylglycerol (2-AG) content, rats received intra-PL infusions of DO34 (1 µg/0.3µL) or vehicle (70% 
DMSO) 30 min prior to a corticosterone (2 mg/kg, ip) or vehicle (10% EtOH) injection. Rats were rapidly 
decapitated 45-min following the injection and brains were removed and flash frozen by submersion in liquid 
nitrogen (total time from decapitation was approximately 90-sec) and stored at −80°C. For tissue dissection, 1 
mm prelimbic prefrontal cortical sections (approx. 3.72 mm to – 2.76 mm from Bregma) were isolated from 
coronal sections on dry ice as described previously (2) and stored at −80°C. Placement of guide cannula was 
visually confirmed to be in the prelimbic cortex during dissection. Tissue samples were weighed and 
homogenized in acetonitrile containing 67 pmol [2H8]AEA and 8 nmol [2H8]2-AG (Cayman Chemical Company, 
Ann Arbor, MI), sonicated for 60 min, and frozen overnight at −20°C to precipitate proteins. Particulates were 
then removed by centrifugation at 1500 x g for 2 minutes at 4°C, after which the supernatant was rapidly 
extracted and concentrated under N2 gas re-suspended in 100% methanol and AEA and 2-AG were isolated and 
quantified by tandem liquid chromatography-mass spectrometry (LC/MS/MS; Agilent Technologies 6460 Triple 
Quad LC/MS), and concentrations were calculated by isotope dilution as previously described (3). 
Histology: To determine the accuracy of guide cannula placements, rats were sacrificed and brains were post-
fixed in 4% paraformaldehyde, cryoprotected in 30% sucrose, and finally 50 µm sections were taken from the 
level of the prelimbic cortex using a cryostat. Tissue sections were mounted onto gelatin-coated slides and 
stained using a cresyl violet nuclear stain. Guide cannula placement was determined to be accurate if the 
injection needle terminated in the prelimbic region of the medial prefrontal cortex. A limited number of rats 
(n=5) did not have bilateral hits for cannula placement and were excluded from the study. In each case, drug 
effects were not observed in rats that had injections outside of the prelimbic cortex. 
Drugs: Cocaine HCl was obtained from the National Institute on Drug Abuse (NIDA) through the NIDA Drug 
Supply Program. Cocaine was dissolved in saline (0.9% bacteriostatic saline). Corticosterone (Steroloids, 
Newport, RI) was dissolved in a 10% EtOH in saline solution, and 2- hydroxypropyl-β-cyclodextrin (HBC)-
conjugated corticosterone (Sigma-Aldrich, St. Louis, MO) was dissolved in saline. AM251 (Sigma-Aldrich, St. 
Louis, MO), WIN-55,212 (Tocris, Bristol, UK), URB502 (Tocris, Bristol, UK), and DO34 (0.1 µg) were made in a 
vehicle containing 10% DMSO in saline. DO34 (1 µg) was made in a vehicle containing 70% DMSO in saline. 
Statistical analysis: Statistical analyses were conducted using SPSS (IBM Analytics, Armonk, NY) or Sigmaplot 
(Systat Software, San Jose, CA) statistics software. For behavioral experiments, lever responding was analyzed 
using two-way repeated measures ANOVA followed by post-hoc testing using Bonferroni-corrected t-tests. For 
electrophysiology experiments, IPSC amplitude was normalized to the baseline. The depression (%) of IPSCs by 
corticosterone was calculated as follows: 100 × [mean amplitude of IPSCs during the last 5 min treatment/mean 
amplitude of baseline IPSCs]. Data sets were compared with Student's t-test. For mass spectrometry, 
endocannabinoid content was analyzed using a two-way ANOVA followed by post-hoc testing. For all analyses, 
statistical significance was defined as p<.05. 
Supplemental Data 
Table S1. Cocaine self-administration and extinction responding. Data represent total active lever responses/2-h 
session for Figures 1, 3, 4 and 5 during days 1 and 14 of cocaine self-administration (SA) and total active lever 
responses/2-h session on the first day of extinction (Ext) and the last day of extinction before reinstatement 
testing for experiments 1 and 2. The number of days to reach extinction criteria for each experiment is also 
reported. Data are represented as mean ± SEM. (EFS, Electric footshock stress; COC, cocaine; CORT, 
corticosterone; PL, prelimbic cortex; AM251, CB1R antagonist; WIN, WIN 55,212-2 CB1R agonist; URB602, 
monoacylglycerol lipase inhibitor; DO34; diacylglycerol lipase inhibitor). 
 Cocaine SA  Extinction  Range of 
Days to Ext 
Average Days 
to Ext 
Experiment no. 
(n) 
SA Day 1 SA Day 14 First Ext Last Ext # Days # Days 
1 EFS/COC; (6) 106.00 ± 
8.10 
123.83 ± 
7.48 
68.50 ± 
13.57 
8.67 ± 
1.43 
5-10 8.00 ± 0.85 
1 CORT/COC; (5) 121.40 ± 
10.18 
114.00 ± 
13.57 
33.2 ± 
13.35 
6.80 ± 
1.56 
5-15 8.80 ± 1.69 
1 PL CORT/ 
COC; (7) 
115.86 ± 
10.98 
137.71 ± 
24.25 
68.85 ± 
7.53 
7.57 ± 
1.57 
5-17 8.28 ± 1.76 
3 PL AM251/ 
EFS/COC; (6) 
123.67 ± 
8.38 
128.33 ± 
6.95 
76.00 ± 
19.24 
7.17 ± 
1.49 
4-12 7.17 ± 1.19 
3 PL AM251/ 
CORT/COC; (6) 
131.00 ± 
15.18 
132.50 ± 
14.32 
71.83 ± 
12.59 
8.83 ± 
1.54 
5-20 8.83 ± 2.30 
4 PL WIN/ 
COC; (6) 
146.33 ± 
17.95 
149.50 ± 
28.00 
68.50 ± 
10.13 
5.17 ± 
2.52 
5-9 6.67 ± 0.56 
4 PL URB602/ 
COC (6) 
112.67 ± 
8.46 
117.33 ± 
6.45 
77.67 ± 
15.08 
8.17 ± 
1.72 
3-9 6.17 ± 0.98 
5 PL DO34/ 
CORT/COC (5) 
112.60 ± 
11.44 
122.60 ± 
18.99 
32.00 ± 
12.41 
5.00 ± 
1.58 
5-13 9.00 ± 1.52 
 
Table S2. Detailed statistics for experiments depicted in Figure 1. Two-way repeated measures (RM) ANOVAs 
were conducted with reinstatement condition and day (extinction, reinstatement) as factors. These were 
followed by separate one-way RM ANOVAs examining responding during extinction and reinstatement testing. 
Post-hoc testing was conducted using Bonferroni-corrected t- tests. * denotes significance. (Ext=extinction; 
Rst=reinstatement; Coc=cocaine, Cort=corticosterone; Sal=saline; Veh=vehicle). 
Figure 1A    
2-way RM ANOVA  Post hoc test: Ext vs Rst  
Condition F(3,15)=18.05, p<.001* No Shock/Sal p>.05 
Day F(1,5)=29.59, p<.01* Shock/Sal p>.05 
Condition X Day F(3,15)=17.11, p<.001* No Shock/Coc p<.05* 
  Shock/Coc p<.01* 
1-way RM ANOVA  Post hoc test: Rst – 
Shock/Coc vs 
 
Extinction F(3,15)=.05, p>.05 No Shock/Sal p=.06 
Reinstatement F(3,15)=19.26, p<.001* Shock/Sal p<.05* 
  No Shock/Coc p<.05* 
Figure 1B    
2-way RM ANOVA  Post hoc test: Ext vs Rst  
Condition F(3,12)=7.38, p<.01* Veh/Sal p>.05 
Day F(1,4)=5.50, p=.07 Cort/Sal p>.05 
Condition X Day F(3,12)=10.30, p<.001* Veh/Coc p>.05 
  Cort/Coc p<.05* 
1-way RM ANOVA  Post hoc test: Rst – 
Cort/Coc vs 
 
Extinction F(3,12)=.55, p>.05 Veh/Sal p>.05 
Reinstatement F(3,12)=9.07, p<.01* Cort/Sal p>.05 
  Veh/Coc p>.05 
Figure 1C    
2-way RM ANOVA  Post hoc test: Ext vs Rst  
Condition F(2,12)=3.99, p<.05* Cort/Sal p>.05 
Day F(1,6)=6.78, p<.05* Veh/Coc p>.05 
Condition X Day F(2,12)=4.89, p<.05* Cort/Coc p<.05* 
1-way RM ANOVA  Post hoc test: Rst – 
Cort/Coc vs 
 
Extinction F(2,12)=1.01, p>.05 Cort/Sal p>.05 
Reinstatement F(2,12)=4.80, p<.05* Veh/Coc p>.05 
 
Table S3. Detailed statistics for experiments depicted in Figure 3. Two-way repeated measures (RM) ANOVAs 
were conducted with reinstatement condition and day (extinction, reinstatement) as factors. These were 
followed by separate one-way RM ANOVAs examining responding during extinction and reinstatement testing. 
Post-hoc testing was conducted using Bonferroni-corrected t- tests. * denotes significance. (Ext=extinction; 
Rst=reinstatement; Coc=cocaine, Cort=corticosterone; Sal=saline; Veh=vehicle). 
Figure 3A    
2-way RM ANOVA  Post hoc test: Ext vs Rst  
Condition F(3,15)=10.64, p<.001* Veh/Shock/Sal p>.05 
Day F(1,5)=8.80, p<.05* Veh/No Shock/Coc p>.05 
Condition X Day F(3,15)=15.71, p<.001* Veh/Shock/Coc p<.01* 
  AM251/Shock/Coc p>.05 
1-way RM ANOVA  Post hoc test: Rst – 
Veh/Shock/Coc vs 
 
Extinction F(3,15)=.61, p>.05 Veh/Shock/Sal p<.05* 
Reinstatement F(3,15)=19.26, p<.001* Veh/No Shock/Coc p<.05* 
  AM251/Shock/Coc p=.06 
Figure 3B    
2-way RM ANOVA  Post hoc test: Ext vs Rst  
Condition F(3,15)=9.52, p<.001* Veh/Cort/Sal p>.05 
Day F(1,5)=11.14, p<.05* Veh/Veh/Coc p>.05 
Condition X Day F(3,15)=6.94, p<.01* Veh/Cort/Coc p<.05* 
  AM251/Cort/Coc p>.05 
1-way RM ANOVA  Post hoc test: Rst – 
Veh/Cort/Coc vs 
 
Extinction F(3,15)=1.41, p>.05 Veh/Cort/Sal p>.05 
Reinstatement F(3,15)=14.39, p<.001* Veh/Veh/Coc p>.05 
  AM251/Cort/Coc p>.05 
 
Table S4. Detailed statistics for experiments depicted in Figure 4. Two-way repeated measures (RM) ANOVAs 
were conducted with reinstatement condition and day (extinction, reinstatement) as factors. These were 
followed by separate one-way RM ANOVAs examining responding during extinction and reinstatement testing. 
Post-hoc testing was conducted using Bonferroni-corrected t- tests. * denotes significance. (Ext=extinction; 
Rst=reinstatement; Coc=cocaine; Sal=saline; Veh=vehicle; WIN=WIN 55,212-2). 
Figure 4A    
2-way RM ANOVA  Post hoc test: Ext vs Rst  
Condition F(2,10)=4.01, p<.05* WIN/Sal p>.05 
Day F(1,5)=6.24, p<.05* Veh/Coc p>.05 
Condition X Day F(2,10)=7.09, p<.01* WIN/Coc p<.05* 
1-way RM ANOVA  Post hoc test: Rst – WIN/Coc vs  
Extinction F(2,10)=0.18, p>.05 WIN/Sal p>.05 
Reinstatement F(2,10)=5.39, p<.05* Veh/ Coc p>.05 
Figure 4B    
2-way RM ANOVA  Post hoc test: Ext vs Rst  
Condition F(2,10)=5.26, p<.05* URB602/Sal p>.05 
Day F(1,5)=8.12, p<.05* Veh/Coc p>.05 
Condition X Day F(2,10)=5.89, p<.05* URB602/Coc p<.05* 
1-way RM ANOVA  Post hoc test: Rst – URB602/Coc 
vs 
 
Extinction F(2,10)=2.94, p>.05 URB602/Sal p>.05 
Reinstatement F(2,10)=7.47, p<.01* Veh/Coc P<.01* 
 
Table S5. Detailed statistics for experiments depicted in Figure 5. Two-way repeated measures (RM) ANOVAs 
were conducted with reinstatement condition and day (extinction, reinstatement) as factors. These were 
followed by separate one-way RM ANOVAs examining responding during extinction and reinstatement testing. 
Post-hoc testing was conducted using Bonferroni-corrected t- tests. * denotes significance. (Ext=extinction; 
Rst=reinstatement; Coc=cocaine; Sal=saline; Veh=vehicle; DO=DO34). 
Figure 5C    
2-way RM ANOVA  Post hoc test: Ext vs Rst  
Condition F(4,16)=5.28, p<.01* Veh/Cort/Sal p>.05 
Day F(1,4)=7.24, p<.05* Veh/Veh/Coc p>.05 
Condition X Day F(3,16)=3.84, p<.05* Veh/Cort/Coc p<.05* 
  DO(0.1)/Cort/Coc p>.05 
  DO(1.0)/Cort/Coc p>.05 
1-way RM ANOVA  Post hoc test: Rst – 
Veh/Cort/Coc vs 
 
Extinction F(4,16)=2.11, p>.05 Veh/Cort/Sal p>.05 
Reinstatement F(4,16)=4.62, p<.01* Veh/Veh/Coc p>.05 
  DO(0.1)/Cort/Coc p>.05 
  DO(1.0)/Cort/Coc p>.05 
 
Supplemental Figure S1. Plasma levels of corticosterone following footshock or systemic corticosterone 
administration. A) Timeline of blood collection. Time points were selected to correspond to the start of the 
reinstatement session in rats tested for behavior. B) 15-min of electric footshock stress (Shock) significantly 
increases plasma levels of corticosterone (n=7-8, **p<.01 compared to No Shock). Systemic administration of 
corticosterone (n=5-11, 2 mg/kg, i.p.) significantly increases plasma levels of corticosterone similar to levels 
observed with footshock (** p<.01, compared to Vehicle). Data are represented as mean ± SEM. 
 
Supplementary Figure S2. Direct administration of the diacylglycerol lipase inhibitor DO34 (1 µg/0.3 µL) into the 
prelimbic cortex (PL) 30-min prior to a systemic injection of corticosterone (CORT; 2 mg/kg, i.p) has no effect on 
PL anandamide (AEA) content (n=7-8, p>.05). 
 
Supplementary Figure S3. Inactive lever responding during extinction and reinstatement tests. There was no 
significant effect of reinstatement condition on lever responding under any condition. A) Inactive lever 
responding corresponding to Fig 1A. B) Inactive lever responding corresponding to Fig 1B. C) Inactive lever 
responding corresponding to Fig 1C. D) Inactive lever responding corresponding to Fig 3A. E) Inactive lever 
responding corresponding to Fig 3B. F) Inactive lever responding corresponding to Fig 4A. G) Inactive lever 
responding corresponding to Fig 4B. H) Inactive lever responding corresponding to Fig 5C. (COC, cocaine; CORT, 
corticosterone; PL, prelimbic cortex; AM251, CB1R antagonist; WIN, WIN 55,212-2 CB1R agonist; URB602, 
monoacylglycerol lipase inhibitor; DO34; diacylglycerol lipase inhibitor). 
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